| ID | 10019 |
| Vaccine Name | JCOVDEN |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Approved |
| Manufacturer | Janssen Pharmaceutical |
| Year of Manufacturing | NA |
| Manufacturing Country | NA |
| Age | NA |
| Dosage | 2 doses 56 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine |
| PMID | 33816047 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | https://www.fda.gov/media/153439/download
|